$TEVA Turnaround may have begun in Teva Pharmaceutical.
Teva Pharmaceutical Industries (NYSE:TEVA) Q3 results:
Revenues: $4,264M (-5.9%).
Key product sales: Copaxone: $397M (-33.9%); Generics: $2,224B (-1.8%).
Net loss: ($314M) (-15.0%); non-GAAP net income: $637M (-8.2%); loss/share: ($0.29) (-7.4%); non-GAAP EPS: $0.58 (-14.7%).
Cash flow ops: $325M (-22.8%).
2019 guidance: Revenues: $17.2B - 17.4B from $17.0B - 17.4B; operating income: $4.0B - 4.2B from $3.8B - 4.2B; EBITDA: $4.5B - 4.8B from $4.4B - 4.8B; EPS: $2.30 - 2.50 from $2.20 - 2.50; free cash flow: $1.7B - 2.0B from $1.6B - 2.0B.
Eli Kalif appointed EVP and Chief Financial Officer effective December 22. He joins the firm from Flex Ltd where he was SVP Finance Global Operations, Components & Services.
Shares up 4% premarket on increased volume.
Previously: Teva Pharmaceutical EPS misses by $0.01, beats on revenue (Nov. 7)
Source Seeking Alpha
Short interest relatively high at 7%
Company profile
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
Revenues: $4,264M (-5.9%).
Key product sales: Copaxone: $397M (-33.9%); Generics: $2,224B (-1.8%).
Net loss: ($314M) (-15.0%); non-GAAP net income: $637M (-8.2%); loss/share: ($0.29) (-7.4%); non-GAAP EPS: $0.58 (-14.7%).
Cash flow ops: $325M (-22.8%).
2019 guidance: Revenues: $17.2B - 17.4B from $17.0B - 17.4B; operating income: $4.0B - 4.2B from $3.8B - 4.2B; EBITDA: $4.5B - 4.8B from $4.4B - 4.8B; EPS: $2.30 - 2.50 from $2.20 - 2.50; free cash flow: $1.7B - 2.0B from $1.6B - 2.0B.
Eli Kalif appointed EVP and Chief Financial Officer effective December 22. He joins the firm from Flex Ltd where he was SVP Finance Global Operations, Components & Services.
Shares up 4% premarket on increased volume.
Previously: Teva Pharmaceutical EPS misses by $0.01, beats on revenue (Nov. 7)
Source Seeking Alpha
Short interest relatively high at 7%
Company profile
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines. The Generic Medicines segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment engages in the provision of core therapeutic areas of central nervous system medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.